CD7 and acute lymphoblastic leukemia: Groups of 8 to ten SCID (CB.17 scid/scid) or NOD/SCID (NOD/LtSz- scid/scid) mice were injected i.v. with two million human HSB-2 T-ALL cells on day 1 (SCID-HSB-2 and NOD/SCID-HSB-2 mice) and treated later with 3 i.v. 10 μg doses of the anti-CD7 antibody HB2 on days 7, 9 and 11 or with a single 10 μg dose of HB2-SAPORIN or a 7.4 μg dose of HB2-F(ab)2-SAPORIN immunotoxin (IT) on day 7.